Our data showed that TIM-3 expression levels on leukemic blasts varied among AML patients, which were in accordance with those of Kikushige et al. and Xu et al. (15, 24) Due to the important role of TIM-3 in AML, it would be intriguing to determine whether varied expression levels of TIM-3 on AML cells influence the immune status and prognosis of AML patients. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.